All In Biotech

Drug Trial Radar · NCT07629778

HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

May 26, 2026

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled, multicenter Phase Ib/II clinical study designed to evaluate the efficacy, safety, and PK characteristics of HL-300 ointment with different concentration regimens for mild-to-moderate AD.

Conditions

  • Atopic Dermatitis

Interventions

  • HL-300Drug

    Group A receives the investigational product at a concentration of 0.25%, BID,4 weeks.

  • PlaceboDrug

    BID, day 7.

  • HL-300Drug

    Group B receives the investigational product at a concentration of 0.5%, BID,4 weeks.

  • HL-300Drug

    Group A receives the investigational product at a concentration of 1.0%, BID,4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eczema Area and Severity Index (EASI)Time frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.